I found this as well

NILO-PD: Completed recruitment of Phase II nilotinib trial for Parkinson's progression

NILO-PD is a Phase II, randomized, placebo-controlled clinical trial evaluating safety and tolerability of nilotinib in 76 people who have had PD for at least five years. The study, funded by The Michael J. Fox Foundation (MJFF), recently completed recruitment -- a major milestone, because research often is hindered by the inability to recruit enough volunteers.

Nilotinib is a U.S. Food and Drug Administration (FDA)-approved treatment for certain cancers. Previous pre-clinical research and a small, open-label Phase I trial found that it also may benefit people with Parkinson's. In NILO-PD, two-thirds of the volunteers take nilotinib and the others take placebo (an inactive pill that looks like nilotinib) for six months. We expect to see results in late 2019.

Research Roundup: Trials Stepping Forward to Potentially Slow Disease and Ease Symptoms | Parkinson's Disease